Neurotrophins Market Size

Neurotrophins Market size is anticipated to reach USD 20 billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of neurotrophins was over USD 10 billion. The neurotrophin market is expected to grow as the aging population increases, leading to a higher prevalence of neurodegenerative diseases. This growth is driven by the demand for innovative treatments and therapies. The market is competitive, with multiple pharmaceutical and biotechnology companies striving to develop and commercialize neurotrophin-based drugs and therapies. Companies may also be working on novel drug delivery methods to enhance the effectiveness of neurotrophin treatments.

The neurotrophins market pertains to the pharmaceutical and biotechnology sector and is related to the development and distribution of neurotrophin-related products and therapies. Neurotrophins are a family of proteins that play a critical role in the growth, development, and maintenance of neurons in the nervous system. They are of particular interest in the fields of neuroscience and neurology, as they have the potential to be used in the treatment of various neurological and neurodegenerative disorders.

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of neurotrophins is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market Genentech, Inc., Regeneron Pharmaceuticals, Inc., Biogen Inc., Amgen Inc., Eli Lilly and Company, Novartis International AG, and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Neurotrophins Market Size